The challenge of selecting the 'right' in vivo oncology pharmacology model

Current Opinion in Pharmacology

Volumn 10, Issue 4, 2010, Pages 391-396

  Firestone, Brant ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHIR 265; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PLX 4032; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ENZYME INHIBITION; GENE MUTATION; GENETIC ENGINEERING; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; STROMAL CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955274583     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.06.012     Document Type: Review

References (49)

1. Kelland L.R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004, 40:827-836.
2. Kuick R., Misek D.E., Monsma D.J., Webb C.P., Wang H., Peterson K.J., Pisano M., Omenn G.S., Hanash S.M. Discovery of cancer biomarkers through the use of mouse models. Cancer Lett 2007, 249:40-48.
3. Sausville E.A., Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006, 66:3351-3354. (discussion).
4. de Jong M., Maina T. Of mice and humans: are they the same?-Implications in cancer translational research. J Nucl Med 2010, 51:501-504.
5. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
6. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008, 68:3077-3080.
7. O'Dwyer M.E., Mauro M.J., Druker B.J. STI571 as a targeted therapy for CML. Cancer Invest 2003, 21:429-438.
8. Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G., et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29:2346-2356.
9. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046.
10. Smalley K.S. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 2010, 11:699-706.
11. Tanaka C., O'Reilly T., Kovarik J.M., Shand N., Hazell K., Judson I., Raymond E., Zumstein-Mecker S., Stephan C., Boulay A., et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26:1596-1602.
12. Mordant P., Loriot Y., Leteur C., Calderaro J., Bourhis J., Wislez M., Soria J.C., Deutsch E. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther 2010, 9:358-368.
13. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
14. Bibby M.C. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 2004, 40:852-857.
15. Suggitt M., Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 2005, 11:971-981.
16. Cespedes M.V., Casanova I., Parreno M., Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006, 8:318-329.
17. Troiani T., Schettino C., Martinelli E., Morgillo F., Tortora G., Ciardiello F. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol 2008, 65:200-211.
18. Helzer K.T., Barnes H.E., Day L., Harvey J., Billings P.R., Forsyth A. Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model. Cancer Res 2009, 69:7860-7866.
19. Baldus S.E., Schaefer K.L., Engers R., Hartleb D., Stoecklein N.H., Gabbert H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010, 16:790-799.
20. Schmid K., Oehl N., Wrba F., Pirker R., Pirker C., Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009, 15:4554-4560.
21. Lee C.H., Xue H., Sutcliffe M., Gout P.W., Huntsman D.G., Miller D.M., Gilks C.B., Wang Y.Z. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005, 96:48-55.
22. Morton C.L., Houghton P.J. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007, 2:247-250.
23. Fichtner I., Rolff J., Soong R., Hoffmann J., Hammer S., Sommer A., Becker M., Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14:6456-6468.
24. Fiebig H.H., Schuler J., Bausch N., Hofmann M., Metz T., Korrat A. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genom Proteom 2007, 4:197-209.
25. Marangoni E., Vincent-Salomon A., Auger N., Degeorges A., Assayag F., de C.P., de P.L., Guyader C., De P.G., Judde J.G., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007, 13:3989-3998.
26. Rubio-Viqueira B., Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009, 85:217-221.
27. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat Rev Immunol 2007, 7:118-130.
28. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
29. Sanchez P.V., Perry R.L., Sarry J.E., Perl A.E., Murphy K., Swider C.R., Bagg A., Choi J.K., Biegel J.A., Danet-Desnoyers G., et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009, 23:2109-2117.
30. Jonkers J., Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2002, 2:251-265.
31. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 2007, 7:645-658.
32. Robles A.I., Varticovski L. Harnessing genetically engineered mouse models for preclinical testing. Chem Biol Interact 2008, 171:159-164.
33. Rudin C.M., Hann C.L., Laterra J., Yauch R.L., Callahan C.A., Fu L., Holcomb T., Stinson J., Gould S.E., Coleman B., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361:1173-1178.
34. Yauch R.L., Dijkgraaf G.J., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
35. Bailey J.M., Mohr A.M., Hollingsworth M.A. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 2009, 28:3513-3525.
36. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
37. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371.
38. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
39. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
40. Charles K.A., Kulbe H., Soper R., Escorcio-Correia M., Lawrence T., Schultheis A., Chakravarty P., Thompson R.G., Kollias G., Smyth J.F., et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009, 119:3011-3023.
41. Ammirante M., Luo J.L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305.
42. Kalialis L.V., Drzewiecki K.T., Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009, 19:275-282.
43. Bir A.S., Fora A.A., Levea C., Fakih M.G. Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes. Anticancer Res 2009, 29:465-468.
44. Nakajima T., Suzuki M., Ando S., Iida T., Araki A., Fujisawa T., Kimura H. Spontaneous regression of bone metastasis from renal cell carcinoma; a case report. BMC Cancer 2006, 6:11.
45. Sittler T., Zhou J., Park J., Yuen N.K., Sarantopoulos S., Mollick J., Salgia R., Giobbie-Hurder A., Dranoff G., Hodi F.S. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res 2008, 14:3896-3905.
46. DiLillo D.J., Yanaba K., Tedder T.F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010, 184:4006-4016.
47. Cohen A.D., Schaer D.A., Liu C., Li Y., Hirschhorn-Cymmerman D., Kim S.C., Diab A., Rizzuto G., Duan F., Perales M.A., et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010, 5:e10436.
48. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-1102.
49. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.